SOX2 and malignant glioma: On average, 15% (range 2–19%) of malignant glioma cells expressed IL-17R and more than 60% of IL-17R+ cells co-expressed the GSC markers CD133, Nestin, and Sox2 (Figure 1 and Supplementary Figure S1).